TrialJournal for immunotherapy of cancer2024

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.

Michael J Overman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.